Dendreon Corporation Appoints Dr. Mitchell H. Gold as Vice President of Business Development.Business and Health/Medical Editors BIOWIRE2K SEATTLE--(BW HealthWire)--June 19, 2001 Dendreon Corporation (Nasdaq:DNDN) today announced that Mitchell H. Gold, M.D. has joined the company as vice president of business development. Dr. Gold is the founder and former president and chief executive officer of Elixis Corporation, a leader in web-based electronic medical records. Dr. Gold is also a former urologist Urologist A physician who deals with the study and treatment of disorders of the urinary tract in women and the urogenital system in men. Mentioned in: Congenital Bladder Anomalies, Lithotripsy, Men's Health, Overactive Bladder urologist at the University of Washington in Seattle. Most recently, Dr. Gold served as vice president of business development and vice president of sales and marketing for Data Critical Corporation (Nasdaq:DCCA DCCA Department of Commerce and Community Affairs DCCA Department of Commerce and Consumer Affairs DCCA Dependable Computing for Critical Applications (Conference) DCCA Debian Common Core Alliance DCCA Dupont Circle Citizens Association ). He serves on the boards of the University of Washington/Fred Hutchinson Cancer Research Center Prostate Cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. Institute, Catalyst Medical Solutions, based in Boston, Mass., and Xenotope Diagnostics of Palo Alto, Calif. "Dr. Gold is a strong addition to the Dendreon management team," said Christopher S. Henney, Ph.D., D.Sc., chief executive officer of Dendreon. "His experience in all aspects of business development and his knowledge of the healthcare industry will be of benefit to the company." Dendreon Corporation (www.dendreon.com) is dedicated to the discovery and development of novel products for the treatment of cancer through its innovative manipulation of the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . Dendreon currently has three therapeutic cancer vaccine candidates in clinical trials-- Provenge(TM), for the treatment of prostate cancer, in Phase III trials; Mylovenge(TM), for the treatment of multiple myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility , in Phase II trials; and APC (1) (American Power Conversion Corporation, West Kingston, RI, www.apcc.com) The leading manufacturer of UPS systems and surge suppressors, founded in 1981 by Rodger Dowdell, Neil Rasmussen and Emanual Landsman, three electronic power engineers who had worked at MIT. 8024, for the treatment of breast, ovarian and colon cancers, in Phase I trials. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion